Cell Biotech Co. Ltd (049960) — Cash Flow Quality Index
Cell Biotech Co. Ltd (049960) has a Cash Flow Quality Index of 1.20x as of September 2025. Operating cash flow of ₩4.15 Billion exceeds net income of ₩3.45 Billion, indicating high earnings quality where cash backs reported profits. Explore debt repayment capacity of Cell Biotech Co. Ltd to assess how comfortably operating cash covers total debt obligations.
Cash Flow Quality Index
Operating Cash Flow
Net Income
Data as of
Cell Biotech Co. Ltd Cash Flow Quality Index (2011–2024)
Historical Cash Flow Quality Index for Cell Biotech Co. Ltd across 14 annual periods. Values consistently above 1.0x indicate high-quality earnings. For the full cash flow conversion analysis, see 049960 cash generation efficiency.
Annual Cash Flow Quality Index for Cell Biotech Co. Ltd (2011–2024)
Year-by-year earnings quality comparison for Cell Biotech Co. Ltd.
| Year | Quality Index | Operating CF (KRW) | Net Income | YoY Change |
|---|---|---|---|---|
| 2024 | 1.27x | ₩19.27 Billion | ₩15.13 Billion | ▲ +2.7% |
| 2023 | 1.24x | ₩7.82 Billion | ₩6.30 Billion | ▼ -19.9% |
| 2022 | 1.55x | ₩12.81 Billion | ₩8.28 Billion | ▲ +7.9% |
| 2021 | 1.43x | ₩14.89 Billion | ₩10.38 Billion | ▼ -52.2% |
| 2020 | 3.00x | ₩9.56 Billion | ₩3.19 Billion | ▲ +112.0% |
| 2019 | 1.41x | ₩10.23 Billion | ₩7.23 Billion | ▲ +96.2% |
| 2018 | 0.72x | ₩13.98 Billion | ₩19.38 Billion | ▼ -41.8% |
| 2017 | 1.24x | ₩22.53 Billion | ₩18.20 Billion | ▲ +27.2% |
| 2016 | 0.97x | ₩17.99 Billion | ₩18.48 Billion | ▼ -6.8% |
| 2015 | 1.04x | ₩18.24 Billion | ₩17.46 Billion | ▲ +9.7% |
| 2014 | 0.95x | ₩9.91 Billion | ₩10.40 Billion | ▼ -17.4% |
| 2013 | 1.15x | ₩8.99 Billion | ₩7.80 Billion | ▲ +14.7% |
| 2012 | 1.00x | ₩6.17 Billion | ₩6.14 Billion | ▼ -4.2% |
| 2011 | 1.05x | ₩5.45 Billion | ₩5.20 Billion | — |